ScholarDeck

Cohort studyOcular immunology and inflammation · 2026

Efficacy of Adalimumab Therapy for Non-Infectious Uveitis in Japanese Patients: Methotrexate Concomitance Across Different Uveitis Etiologies and the Effect of Dose Spacing.

Tatsuya Sakamoto, Tomona Hiyama, Mao Tanabe … Yosuke Harada

OphthalmologyCohort study

Most patients on adalimumab had inactive uveitis after 12 months of treatment

Efficacy of Adalimumab Therapy for Non-Infectious Uveitis in Japanese Patients: Methotrexate Concomitance Across Different Uveitis Etiologies and the Effect of Dose Spacing.

Tatsuya Sakamoto … Yosuke Harada

Ocular immunology and inflammation · 2026

Purpose

To evaluate the long-term efficacy of adalimumab (adalimumab) in Japanese patients with non-infectious uveitis (non-infectious uveitis), with particular attention to etiologic differences in methotrexate (methotrexate) requirements and the feasibility of adalimumab dose spacing.

Methods

This retrospective study included patients with chronic non-infectious uveitis or sclerouveitis treated with adalimumab for more than 6 months.

n = 160 eyes

Results

61.5%

checked eye by eye, most had no active inflammation after a year

n = 160 eyes

More results

Adalimumab reduced systemic corticosteroid dosage (mean 13.7 mg/day at baseline to 0.9 mg/day at 12 months; Wilcoxon signed-rank test p < 0.0001 for baseline-to-12-month change) and improved best-corrected visual acuity (mixed-effects model: p = 0.035 at 12 months) and inflammation markers.

More results

Patients with late- or chronic-stage Vogt-Koyanagi-Harada disease/sympathetic ophthalmia showed a trend toward a higher requirement for methotrexate concomitance than Behçet's disease patient.

Over half of the 24 patients attempting dose spacing relapsed (14/24), but disease control was regained by shortening intervals.

“

Conclusion · 1 of 2

Adalimumab effectively controlled non-infectious uveitis and provided significant steroid-sparing benefits.

Conclusion · 2 of 2

Possible etiology-dependent differences in methotrexate requirements and relapse risk during dose spacing, support the optimization of individualized, closely monitored treatment.

Post

Efficacy of Adalimumab Therapy for Non-Infectious Uveitis in Japanese Patients: Methotrexate Concomitance Across Different Uveitis Etiologies and the Effect of Dose Spacing.

Most patients on adalimumab had inactive uveitis after 12 months of treatment

Related papers